Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 17;22(5):157-161.
doi: 10.1097/CLD.0000000000000085. eCollection 2023 Nov.

Updates in nonalcoholic fatty liver disease

Manida Wungjiranirun  1 , Nicole Wong  2 , Janice Jou  1 , Cynthia A Moylan  3
Affiliations

Updates in nonalcoholic fatty liver disease

Manida Wungjiranirun et al. Clin Liver Dis (Hoboken). .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Janice Jou receives grants from Gilead. Cynthia Moylan advises Boehringer Inghelheim. She receives institutional grants from Exact Sciences and GSK. The remaining authors have no conflicts to report.

Figures

None
Graphical abstract
FIGURE 1
FIGURE 1
Management of NAFLD. Abbreviations: DPP4, dipeptidyl peptidase IV; FXR, farsenoid X receptor; GLP1, glucagon-like peptide 1; SGLT2, sodium-glucose cotransporter-2.
FIGURE 2
FIGURE 2
Populations at risk for NAFLD with clinically significant fibrosis. Abbreviation: DM, diabetes mellitus.
See this image and copyright information in PMC

References

    1. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. . The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–57. - PubMed
    1. Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wai-Sun Wong V, Wright E, et al. . Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology. 2021;161:1657–69. - PMC - PubMed
    1. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. . AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797–835. - PMC - PubMed
    1. Younossi Z, Henry L. Contribution of alcoholic and nonalcoholic fatty liver disease to the burden of liver-related morbidity and mortality. Gastroenterology. 2016;150:1778–85. - PubMed
    1. Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. . Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65:1557–65. - PMC - PubMed